Account
Havas acquires US-based Gemini Healthcare
MUMBAI: Havas acquired Gemini Healthcare LLC, a full-service healthcare marketing, communications and consulting agency focused on the interrelationships between pharmaceutical and biotech companies, their products and payers.
Gemini Healthcare, which has revenue in excess of $5 million, has offices in NY and Connecticut and its main clients include Jazz, Astra Zeneca and Pfizer.
With a track record of more than 10 years, Gemini Healthcare is currently led by Gary Ainsworth and Michael Pill. Ainsworth will serve as CEO and Pill will serve as CCO to the new company Havas Gemini – the result of combining Gemini Healthcare with existing Havas group Managed Edge.
“Havas Health is continually building its capabilities worldwide and is a prime contributor to our strong performance as a company. The addition of Gemini Healthcare is a first-rate example of how Havas Health works strategically, looking for groups with complementary skills to bring more benefits to our health and wellness clients,” said Havas Group CEO Yannick Bollore.
“We are very pleased to bring Gemini Healthcare and its team into the Havas Health family – and to welcome Gary as CEO and Michael as CCO of our newly formed Havas Gemini. Gemini is a very strong strategic fit for us; it shares our focus on future-forward thinking and adds to our payer marketing offering within the network, ensuring that we continue to expand our footprint in the health and wellness space,” said Havas Health CEO Donna Murphy.
“We view the merger with Havas as synergistic and a positive step for both companies,” added Pill.
“It’s an exciting prospect to bring together two entrepreneurial and innovative groups – Havas, with its diverse network of talented people, energy and new ideas, and Gemini, with its payer expertise and strong focus on cutting-edge sectors,” said Ainsworth.
Gemini Healthcare develops innovative, intelligent and integrated solutions to meet its clients’ unique challenges. Exclusively devoted to creating innovative brand campaigns and managed care strategies for its clients, its passion for brand profiling, segment marketing, claims-based analyses, and unwavering payer focus have helped change the way key healthcare stakeholders think and act.
MUMBAI: BigTrunk Communications, an integrated digital marketing agency known for driving brand transformations across industries, has been awarded the digital marketing mandate for Soframycin, one of India’s most trusted antiseptic cream brands from the EncubeEthicals portfolio. With this collaboration, Soframycin makes its debut into the digital space, aiming to amplify its presence across India through compelling social media narratives and data-led campaigns. BigTrunk will lead the brand’s digital strategy and execution, with a focus on connecting Soframycin’s legacy of trust with today’s health-conscious and digitally engaged audience.
Soframycin has been a household name for generations, widely recognized for its efficacy in treating cuts, burns, and wounds. Backed by the scientific rigor and pharmaceutical expertise of EncubeEthicals, a pharmaceutical powerhouse since 1998, the brand benefits from the expertise of over 1,400 professionals, including more than 200 R&D specialists and a robust team of quality experts. With a presence in over 50 countries, Encube’s commitment to excellence in topical formulations adds deep credibility to Soframycin’s legacy. Now, as the brand enters the digital space, BigTrunk Communications will lead the charge in reimagining Soframycin’s story—creating modern, relatable digital experiences that stay true to its heritage.
“As we take Soframycin into its next chapter of growth, embracing digital media is not just a strategy but a necessity. We wanted a partner who could translate our scientific credibility into engaging, relatable content for today’s audience,” said Soframycin vice president – marketing, Ajay Rawal. “BigTrunk’s deep understanding of healthcare communications and digital behavior makes them the ideal partner to build meaningful narratives around wound care, trust, and wellbeing.”
“Soframycin is more than a product—it’s a legacy deeply rooted in care and science,” added BigTrunk Communications founder & managing director Bharat Subramaniam. “We’re excited to take on this responsibility of guiding a heritage brand into the digital world. Our focus will be on creating contextual storytelling and purpose-driven campaigns that bring Soframycin closer to Indian families, both old and new.”
